StemCell Therapy

ThermoGenesisHoldingsInc . (NASDAQ:THMO) was upgraded by equities research analysts at ValuEngine from a hold rating to a buy rating in a note issued to investors on Tuesday, January 14th, ValuEngine reports.

Separately, HC Wainwright restated a buy rating and issued a $7.50 price target on shares of ThermoGenesisHoldingsInc . in a research note on Thursday, November 21st.

THMO traded up $0.05 during trading on Tuesday, hitting $5.01. 6,800 shares of the stock were exchanged, compared to its average volume of 59,586. The company has a market cap of $14.25 million, a price-to-earnings ratio of -1.44 and a beta of 1.02. The company has a quick ratio of 1.36, a current ratio of 1.96 and a debt-to-equity ratio of 1.16. The companys fifty day simple moving average is $4.20. ThermoGenesisHoldingsInc . has a 1-year low of $2.35 and a 1-year high of $7.00.

ThermoGenesisHoldingsInc . (NASDAQ:THMO) last released its earnings results on Tuesday, November 19th. The company reported ($0.78) earnings per share (EPS) for the quarter, missing the Zacks consensus estimate of ($0.12) by ($0.66). ThermoGenesisHoldingsInc . had a negative net margin of 89.98% and a negative return on equity of 87.88%. The company had revenue of $4.06 million during the quarter, compared to analyst estimates of $4.80 million. On average, analysts forecast that ThermoGenesisHoldingsInc . will post -0.16 EPS for the current fiscal year.

ThermoGenesisHoldingsInc . Company Profile

ThermoGenesis Holdings, Inc develops, commercializes, and markets a range of automated technologies for cell-based therapies in the United States, China, rest of Asia, Europe, and internationally. The company operates through two segments, Clinical Development and Device. It offers AutoXpress System, an automated system for the isolation, collection and storage of hematopoietic stem cell concentrates derived from cord blood and peripheral blood; Point-of CareXpress System for the rapid, automated processing of autologous peripheral blood or bone marrow aspirate derived stem cells; CAR-TXpress System that addresses the critical unmet need for chemistry, manufacturing and controls improvement of the emerging CAR-T therapies for cancer patients; BioArchive Cryopreservation System, an automated, robotic, liquid nitrogen controlled-rate-freezing and cryogenic storage system for stem cell samples and clinical products; and manual disposables.

Further Reading: Price to Earnings Ratio (PE) Basics

To view ValuEngines full report, visit ValuEngines official website.

Receive News & Ratings for ThermoGenesisHoldingsInc . Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ThermoGenesisHoldingsInc . and related companies with MarketBeat.com's FREE daily email newsletter.

Read more:
ThermoGenesisHoldingsInc . (NASDAQ:THMO) Raised to Buy at ValuEngine - Riverton Roll

This entry was posted on February 5, 2020 at 11:42 pm and is filed under Stem Cell Negative. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |